Connect with us


Santen Acquires Eyevance in $225M Deal

The company develops topical ophthalmic products.




Osaka-based Santen has acquired Fort Worth, TX-based Eyevance, which develops topical ophthalmic products, for $225 million.

“We’re very pleased to have entered into this agreement,” said Shigeo Taniuchi, Santen president and CEO. “Through this purchase, we will quickly establish a business base in the U.S. and both humbly face and further contribute to the needs of a greater number of patients by offering more value. At the same time, we will accelerate global business rollout by gaining access to the U.S. and our presence in the market, aiming for even further corporate growth and contribution to ophthalmic treatments for people around the world.”

Oprah in Götti … and More Celebrity Eyewear Picks
Photo Gallery

Oprah in Götti … and More Celebrity Eyewear Picks

Fun with Tape … and More Highly Creative DIY Eyewear Fixes From Your Clients
Photo Gallery

Fun with Tape … and More Highly Creative DIY Eyewear Fixes From Your Clients

38 Boss Memes That Everyone in Retail Can Relate To

38 Boss Memes That Everyone in Retail Can Relate To

Santen Holdings U.S. Inc. bought all outstanding shares of Eyevance Pharmaceuticals Holdings Inc. Eyevance is now a wholly owned subsidiary of Santen. Visovanq (sterile vancomycin ophthalmic ointment) and Nexagon (ophthalmic gel for persistent corneal epithelial defects), both of which were being developed by Eyevance, were carved out of the transaction with Santen and are excluded from the purchase.

Founded in 2017, Eyevance has developed and commercialized topical ophthalmic products targeting the ocular surface and anterior segment. Within this area of focus, Eyevance currently offers anti-inflammatory, anti-allergic, anti-fungal, anti-infective/anti-inflammatory fixed combination, and tear lubricant products. Eyevance’s current commercialization strategy is supported by a national sales team exclusively targeting ophthalmologists, optometrists and allergists throughout the U.S.

“Eyevance is proud of its accomplishments over the past three years and looks forward to joining Santen, one of the leading ophthalmic companies worldwide, with its innovative R&D expertise and legacy of global success,” said co-founders Jerry St. Peter, CEO and director, and Jason Werner, COO, Eyevance Pharmaceuticals LLC, in a press release. “We are excited to become part of Santen’s U.S. organization, to work in collaboration to further strengthen the existing commercial business. As Eyevance embarks on this new journey with Santen, we sincerely appreciate the Eyevance Team and its shareholders for their unwavering support and continuous pursuit of excellence.”




Introducing CrizalⓇ Rock™

Did you know three out of four people wipe their lenses on their clothes?* Or that one out of three people accidentally drop their glasses at least once a week?* It's no surprise, then, that 93 percent of wearers consider scratch-resistance an important characteristic when choosing lenses.* To prove the durability of new Crizal Rock lenses, we ran tests inspired by real life situations. To learn more about new Crizal Rock, the most scratch-resistant Crizal No-Glare lenses ever made, visit *Study conducted by ⒸIpsos – Risky behaviors of eyeglass wearers - consumer quantitative research 2019 - declarative results - USA - n= 2345 eyeglass wearers

Promoted Headlines

Most Popular